Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease

Table 2 Biochemical and imaging characteristics of the study cohort

Parameter/score	mean ± SD
Platelets (× 103/µL)	126.12 ± 73.48
AST (U/L)	62.65 ± 54.04
ALT (U/L)	43.61 ± 38.15
Total bilirubin (mg/dL)	2.40 ± 2.76
Sodium (mEq/L)	135.98 ± 4.03
Potassium (mEq/L)	4.18 ± 0.54
Creatinine (mg/dL)	0.86 ± 0.23
Albumin (g/dL)	3.64 ± 0.79
INR	1.37 ± 0.40
MELD 3.0 score	13.75 ± 6.14
ALBI score	-2.14 ± 0.83
FIB-4 index	6.58 ± 6.21
Native SI segment III	147.25 ± 26.15
Native SI segment VI	167.20 ± 24
Native SI segment VIII	153.90 ± 19.57
Native SI caudate lobe	161.91 ± 22.95
Native SI global	157.56 ± 21.28
Hepatobiliary SI segment III	230.75 ± 55.40
Hepatobiliary SI segment VI	262.60 ± 59.38
Hepatobiliary SI segment VIII	245.85 ± 50.18
Hepatobiliary SI caudate lobe	255.50 ± 57.92
Hepatobiliary SI global	248.68 ± 53.90
HE segment III	83.50 ± 37.16
HE segment VI	95.40 ± 43.01
HE segment VIII	91.95 ± 36.72
HE caudate lobe	93.59 ± 40.90
HE global	91.11 ± 38.15

ALBI: Albumin-Bilirubin score; ALT: Alanine aminotransferase; AST: Aspartate Aminotransferase; FIB-4: Fibrosis-4 score; HE: Hepatic enhancement; INR: International Normalized Ratio; MELD: Model for End-Stage Liver Disease; SD: Standard deviation; SI: Signal intensity.